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Background. Even though altered metabolism representing a hallmark of cancer was proposed nearly a century ago, recent tech-
nological advances have allowed investigators to continue uncovering a previously unrecognized complexity of metabolic pro-
grams that drive tumorigenesis beyond that of aerobic glycolysis.
Methods. The bioenergetic state of a diverse panel of glioblastoma models, including isogenic lines derived from a genetically
engineered adult astrocytic mouse model and patient-derived glioblastoma stem cells, was determined at baseline and in
stressed conditions. Mechanisms contributing to the discovered metabolic phenotypes were determined through molecular
and chemical perturbation, and their biological consequences were evaluated in vivo and in patient samples.
Results. Attenuated mitochondrial reserve capacity was identified as a common metabolic phenotype in glioblastoma lines. This
phenotype was linked mechanistically with the capacity of Ras-mediated signaling to inhibit pyruvate dehydrogenase (PDH) ac-
tivity through downregulation of PDH phosphatase (PDP) expression. PDP1 repression was validated clinically in patient-derived
samples, suggesting that aberrant cellular signaling typical of glioblastoma actively modulates PDH activity. This phenotype was
reversed through both chemical and molecular perturbation. Restoration of PDH activity through stable expression of PDP1-
impaired tumorigenic potential.
Conclusions. These findings support the central role that PDH regulation plays as a downstream consequence of aberrant signaling
associated with gliomagenesis and the scientific rationale to continue to develop and test clinical strategies designed to activate
PDH as a form of anticancer therapy in glioblastoma.
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The current concept that altered metabolism represents a hall-
mark of cancer was initially proposed by Otto Warburg nearly a
century ago.1,2 His seminal observation involved the unique ca-
pacity of cancer to perform aerobic glycolysis, or high fermen-
tative metabolism of glucose, resulting in production and
release of lactic acid even in the presence of adequate oxygen.
It has been inferred that these observations were a direct and
passive consequence of damaged mitochondria in cancer cells;
however, subsequent studies have not supported this notion,
demonstrating oxidative phosphorylation to continue to play
an active role in tumor metabolism.3,4 Further, continued inves-
tigations are uncovering a previously unrecognized complexity
of metabolic programs that actively drive tumorigenesis be-
yond that of aerobic glycolysis. Through dynamic metabolic re-
modeling, which includes anabolic metabolism, anapleurosis,
lipid remodeling, and altered redox balance, specific cells are
able to acquire a selective advantage within a specific microen-
vironment.5 – 8
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The World Health Organization (WHO) classifies glioma into
grades I–IV, based on histological features that play a central
role in prognosis and guiding clinical management. For ex-
ample, patients with grade I tumors are typically cured follow-
ing surgical resection, while patients diagnosed with grade IV
tumors (ie, glioblastoma [GBM]) have a median survival of ap-
proximately 1 year despite aggressive multimodality treatment
consisting of surgery, radiation therapy, and chemotherapy.9
Beyond histological features, considerable progress has been
made in understanding the underlying biology of glioblastoma.
For example, whole genome sequencing performed by The Can-
cer Genome Atlas (TCGA) Research Network has identified 3 clear
nodes of genetic alterations, which include alterations in recep-
tor tyrosine kinase signaling, p53, and Rb pathways.10 The phos-
phatidylinositol 3′ kinase (PI3K) signaling pathway represents
one of the common signaling pathways that is aberrantly acti-
vated in GBM. Stimulation initiates a signaling cascade that ulti-
mately results in activation of the prosurvival signal Akt, which is
associated with increasing tumor grade, decreased levels of ap-
optosis, and adverse clinical outcome in glioma.11 A parallel
pathway commonly activated in GBM is the ERK/MAPK pathway,
which leads to cellular proliferation and tumor progression.12,13
Despite these advancements in our understanding of up-
stream events signaling tumorigenesis, their functional conse-
quence or resultant metabolic alterations contributing to their
aggressive phenotype, remain unclear. Since tumors have ac-
cess to a wide variety of genetic and/or epigenetic modifica-
tions, this level of understanding may be particularly relevant
because there are a limited number of metabolic strategies
that cancer cells can employ to drive an aggressive phenotype,
suggesting the potential for aberrant metabolic programs to
serve as cancer-specific therapeutic targets. Accordingly, re-
cent technological advancements have provided investigators
with the opportunity to gain further insight into the underlying
metabolism of tumors. One approach is through metabolomic
profiling, which is the global quantitative assessment of endog-
enous metabolites within a biological system. This line of inves-
tigation has identified targetable metabolic phenotypes that
are consistent with anabolic metabolism in GBM corresponding
with clinical outcomes.5,14 Another approach is through under-
standing the metabolic phenotype of GBM by studying its bio-
energetic state, which provides insight into relative reliance on
glycolysis and/or oxidative phosphorylation.15,16 Although
knowledge of the metabolic state of cells at baseline may be
informative, since the typical tumor microenvironment pre-
sents diverse metabolic challenges, we hypothesized that
unique metabolic responses elicited during stressed conditions,
including glycolytic and/or mitochondrial reserve capacities,
could provide more relevant insight into metabolic phenotypes
associated with tumorigenesis. In this report using a diverse
panel of GBM models, we identified attenuated mitochondrial
reserve capacity as a consistent metabolic phenotype. We
then went on to demonstrate that this phenotype was driven
by Ras-mediated signaling, which actively regulated pyruvate
dehydrogenase (PDH) activity through PDH phosphatase (PDP)
expression. Further, we demonstrated that this phenotype
could be reversed through both chemical and molecular pertur-
bation, and more importantly, restoring PDH activity impaired
tumorigenesis, supporting the therapeutic potential for target-
ing this metabolic program in GBM.
Materials and Methods
Cell Culture
Human GBM cell lines U251 and T98G, G179, G144, and Human
Astrocyte-SV40 (NHA) were obtained and grown in conditions
described previously.17,18 T, TP, TR, and TRP lines were generat-
ed and grown as previously described.19 Mesenchymal (MES83,
MES326) and proneural (PN19 and PN84) glioma stem cells
(GSCs) were generated and grown as previously described.20
AZD6244 (1 mM) and MK2206 (100 nM) were purchased from
Selleckchem.
Cellular Bioenergetics
Extracellular acidification rate (ECAR), oxygen consumption rate
(OCR), and spare respiratory capacity were measured using the
Seahorse XF24 (Seahorse Bioscience).14 For spare respiratory
capacity measurements, the mitochondrial stress kit (Seahorse
Bioscience) was used, consisting of oligomycin (1 mM), carbonyl
cyanide-4-(trifluoromethoxy)phenylhydrazone (FCCP) (300 nM),
rotenone (1 mM), and antimycin (1 mM). Mitochondrial isola-
tion was performed using methods previously described14
with equimolar concentrations of glucose and pyruvate
(1 mM). Floating cells were analyzed by placing 100 000 cells
in a volume of 10 mL into the central well of the microplate
and allowing them to stabilize for 10 minutes. A screen specif-
ic for the microplate was then firmly laid over the well without
overflow of the media; 500 mL of assay media were then
added to the cells and left in a non-CO2 incubator for 45 min-
utes prior to obtaining readings. Readings were normalized to
total protein, and data were analyzed using Seahorse soft-
ware, with the unpaired t test being applied to test the signifi-
cance of change. Results were representative of at least 3
independent experiments.
Pyruvate Dehydrogenase Activity
A PDH enzyme activity microplate assay kit (Abcam) was used
to determine PDH activity. Results are representative of at least
3 independent experiments.
Western Blot and Reverse Transcriptase Polymerase
Chain Reaction
Western blot, reverse transcriptase (RT-)PCR, and image quan-
tification were performed using methods previously de-
scribed.18 Antibodies used for Western blot included PDH
459400, (Invitrogen), phospho-PDH ab177461 (Abcam), PDP1
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Establishment of Stable Pyruvate Dehydrogenase
Phosphatase 1-overexpressing Cells
Human PDP1 catalytic subunit 1 cDNA/ORF (ccsbBroad304_
03447) was cloned into vector pLX304-Blast-V5 in DH5a
obtained as glycerol stock. Plasmids were isolated from the cul-
ture, quantitated, and transfected into TR cells using methods
previously described.14
Animal Handling
All in vivo experiments were performed according to institution-
al guidelines and approved by the Institutional Animal Care and
Use Committee. Flank-xenografts were established in athymic
nu/nu mice (Charles River Laboratories) using methods previ-
ously described.14
Statistical Analysis
Statistical analysis was done using the Student t test unless
otherwise indicated.
Results
Baseline Bioenergetics of Glioblastoma Cell Lines
We utilized a diverse panel of glioma cell models to provide in-
sight into relative reliance on glycolysis and/or oxidative phos-
phorylation in GBM. These included established GBM cell lines
(U251 and T98G), normal human astrocytes (NHAs), glioma
neural stem (GNS) lines (G144 and G179),17 patient-derived
proneural (PN84, PN19), and mesenchymal (M83, M326)
GSCs, which recapitulate the aggressive, invasive phenotype
of GBM.20 In addition, we applied a novel, genetically engi-
neered mouse (GEM) cell line model to provide insight into spe-
cific signaling pathways that may be driving observed
differences in metabolism. Specifically, primary lines of astro-
cytes were generated from a series of conditional GEM models
in which 1 or 2 of the 3 core GBM pathways were genetically
targeted, as previously described.19,21 After Cre-mediated re-
combination, these mice express (i) N-terminal 121-amino
acid truncation mutant of SV40 large T antigen (T) from the
human glial fibrillary acidic protein promoter, which inactivates
all 3 Rb family proteins; (ii) constitutively active KrasG12D mu-
tant (R); and/or (iii) homozygous Pten deletion (P). Although Ras
is an uncommon stochastic mutation in GBM, its downstream
signaling intermediates are frequently aberrant in GBM, and
causal roles of Ras network aberration in GEM high-grade astro-
cytoma have been validated in several engineered mouse stud-
ies.22 Systematic characterization of primary astrocytes
generated from this model have demonstrated that both Rb in-
activation and Ras activation (TR) are required for high-grade
glioma tumorigenesis, and the incidence of both tumor and
high-grade glioma development was increased when com-
bined with Pten loss (TRP). As an initial investigation, we evalu-
ated baseline metabolism of the described lines using the
Seahorse Extracellular Flux Analyzer (XF24). The capacity of
this platform to measure OCR and proton production (ECAR), in-
dicative of oxidative phosphorylation and glycolysis, respective-
ly, can thereby provide an overall assessment of the metabolic
state of each individual line.14,16,23 Specifically, by plotting OCR
as a function of ECAR, relative utilization of glycolysis and oxi-
dative phosphorylation can be defined along with the energetic
state of an individual cell line;23 (Supplementary material,
Fig. S1A).
Clear metabolic heterogeneity was observed in cell lines
grown in culture (Fig. 1). As expected with the established cell
lines, normal astrocytes had a high OCR (470+29 pmoles/min)
and low ECAR (9+6 mpH/min), suggesting a high reliance on
oxidative phosphorylation in these nonmalignant cells
(Fig. 1A). Further, both GBM cell lines (U251 and T98G) demon-
strated expected high levels of ECAR (59+4 and 52+2 mpH/
min, respectively), which is consistent with aerobic glycolysis.
However, these lines also demonstrated relatively high levels
of baseline oxidative phosphorylation, with U251 cells utilizing
mitochondrial respiration at rates similar to those of NHA
(527+70 pmoles/min). The GNS lines also demonstrated high
levels of mitochondrial respiration (G144: 590+29 and G179:
571+2 pmoles/min) but relatively low ECAR (G144: 18+3
and G179: 10+1 mpH/min) when compared with established
GBM lines (Fig. 1B). Interestingly, the aggressive mesenchymal
GSCs had significantly higher levels of ECAR (M83: 26+3 and
M326: 35+2 mpH/min) and modestly increased OCR (M83:
320+38and M326: 442+55 pmoles/min) when compared
with the proneural GSCs (PN19: 3+1 mpH/min and 190+
12 pmoles/min; PN84: 6+1 mpH/min and 277+25 pmoles/
min), suggesting a lower energetic state in these less aggres-
sive cells. This supports the concept of metabolic heterogeneity
between GBM subtypes and the role metabolism may play in
Fig. 1. Baseline metabolic profiles of glioblastoma cells. The oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) were
plotted against one another to define the bioenergetic state of the described cell lines.
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their underlying aggressiveness. However, this metabolic pat-
tern was not recapitulated in the T/R/P model system
(Fig. 1C). When evaluating OCR, the T and TP lines, which
have a low incidence of tumorigenicity and/or are more consis-
tent with low-grade glioma when grown in vivo,19,21 demon-
strated relatively high levels of OCR (T: 484+27 and TP 454+
33 pmoles/min) when compared with the more aggressive TR
and TRP lines (TR: 202+12 and; TRP 294+11 pmoles/min),
however, the TR and TRP lines were not associated with an ex-
pected increase in ECAR (T: 7+2; TP 14+3; TR: 3+2; TRP 9+
2 mpH/min). Collectively, based on the heterogeneity observed
in these studies, baseline metabolism was inconsistent in both
differentiating the metabolic phenotype of cancer cells from
nontransformed cells and predicting the underlying aggressive-
ness of an individual cancer line.
Glioblastoma Cell Lines Have an Attenuated Spare
Respiratory Capacity
Since baseline cellular metabolism demonstrated a limited ca-
pacity in providing insight into tumor-specific metabolism, we
extended our investigation to further characterize the respira-
tory phenotype of these lines by defining their mitochondrial re-
serve capacities. As the above studies suggested, Ras signaling
(TR and TRP) attenuated baseline OCR, and these specific lines
were associated with the aggressive phenotype of GBM; initial
investigations were performed using the isogenic T/R/P model.
These studies were performed by metabolically perturbing indi-
vidual lines by adding specific compounds in succession and
thereby shifting the bioenergetic profile of the cells, which rep-
resents a methodology derived from established approaches
for studying mitochondria.15 In these studies, cells were first
treated with the ATP synthase inhibitor oligomycin, thereby de-
creasing OCR associated with ATP synthesis. Next, cells were ex-
posed to FCCP, which is an uncoupling agent that dissipates the
mitochondrial membrane potential and leads to rapid and
maximal OCR without generating ATP. The spare respiratory ca-
pacity (SRC) of a cell line is defined as the quantitative differ-
ence between the maximal uncontrolled OCR and initial basal
OCR, as described in Supplementary material, Fig. S1B. Cells
were subsequently exposed to the mitochondrial inhibitors ro-
tenone and antimycin A, thereby, shutting down mitochondrial
respiration and allowing calculation of the mitochondrial and
nonmitochondrial fractions contributing to respiration. Both
the Rb mutated T and TP lines, which again typically do not
develop high-grade gliomas in vivo,19,21 demonstrated similar
respiratory phenotypes with significant increases in OCR follow-
ing decoupling that resulted in SRCs of 120%+17% and 86%+
11%, respectively. However, the addition of a mutation in Ras,
demonstrated in both TR and TRP lines, exhibited attenuated
maximal OCR following decoupling that only returned back to
baseline levels and resulted in diminished SRC (TR¼ 8%+
0.4% and TRP¼ 11%+0.4%; Fig. 2A and B). This pattern was
consistent when tested in our other model systems. For exam-
ple, the respiratory phenotype of normal astrocytes was similar
to the T and TP lines and resulted in a significant SRC of 106%+
8% (Fig. 2C and D). However, both the established GBM lines
and invasive GNS lines demonstrated an attenuated SRC similar
to the TRP and TR lines (Fig. 2E and F). This concept was further
supported when we compared the respiratory phenotype
between GSC subtypes. The proneural GSCs, which demonstrat-
ed slow growth in vivo with minimal angiogenesis and necro-
sis,20 demonstrated a mitochondrial phenotype consistent
with normal astrocytes (ie, SRC of 112%+3% and 114%+
8% in PN19 and PN84 cells, respectively). The rapidly growing,
invasive mesenchymal GSC lines, however, demonstrated an
attenuated SRC (Supplementary material, Fig. S2A and B). Col-
lectively, these findings suggest that an attenuated SRC may
represent a metabolic phenotype of GBM and contribute to-
wards its aggressive biology. We extended our investigations
to determine if mitochondrial potential could serve as another
tool for determining cell-autonomous metabolic heterogeneity.
Despite clear differences in metabolism between T and TR cells,
no appreciable differences were observed in how this translated
to steady-state mitochondrial function (as measured by mem-
brane potential) (Supplementary material, Fig. S3). This sug-
gests that many factors may influence a cell’s energy
requirements and that baseline evaluation of metabolism in
vitro may be limited for elucidating how they translate into its
metabolic phenotype.
Ras-mediated Signaling Actively Modulates Spare
Respiratory Capacity
Next, we investigated the potential mechanism underlying the
observed changes in respiratory phenotype. As in the initial in-
vestigation, we determined if observed changes in reserve ca-
pacity were hardwired in the mitochondria or if they could be
modulated through cell signaling. Mitochondria were isolated
from both U251, which demonstrated an attenuated SRC,
and normal astrocytes by using methods previously de-
scribed.14 Interestingly, SRC was identical in isolated mitochon-
dria in these lines, suggesting that the observed changes in
mitochondrial phenotype may be actively modulated through
cellular signaling (Supplementary material, Fig. S2C). Since
our GEM lines demonstrated that Ras-pathway activation con-
tributed to the observed attenuated SRC, we next sought to
determine if this respiratory phenotype could be reversed
through signaling inhibition. To test this, we exposed TR cells
to the MEK inhibitor AZD6244 and the Akt inhibitor MK2206,
which represent downstream mediators of 2 of the most ex-
tensively studied effectors of Ras signaling (ie, Raf and PI3K, re-
spectively24) with initial studies confirming target engagement
(Supplementary material, Fig. S2D). In the TR line, baseline OCR
and OCR remained unchanged following exposure to the ATP
synthase inhibitor oligomycin when compared with vehicle con-
trol following 24 hour pretreatment with each agent (Fig. 3A).
However, both Akt and MEK inhibition independently demon-
strated the capacity to reverse the previously described atten-
uated respiratory capacity following decoupling to determine
maximal OCR and SRC, resulting in 13%+0.1% and 28%+
0.4% increases in reserve capacities, respectively (Fig. 3A and
B). Interestingly, combining Akt and MEK inhibition led to a fur-
ther increase in SRC (38%+0.5%), suggesting redundancy in
the ability of signaling pathways to influence the mitochondrial
phenotype. Similarly, MEK and/or Akt inhibition reverted the at-
tenuated oxidative reserve capacity in U251 and G179 cells, al-
though their relative reliance on each pathway appeared
cell-line dependent (Supplementary material, Fig. S4A–D). Col-
lectively, these findings suggest that Ras-mediated signaling
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actively modulates SRC. We went on to determine if baseline
levels of Akt or MEK activation could be used to determine a
cell’s SRC and/or differential response to pathway inhibition.
Unfortunately, this line of investigation failed to provide further
insight into our findings (Supplementray material, Fig. S5). For
example, in the isogenic TRP model, Ras mutation increased
Akt activation, while ERK remained relatively unchanged,
which supported this line’s increased metabolic response to
Akt inhibition. U251 cells demonstrated relatively low Akt acti-
vation, supporting its minimal response to Akt inhibition when
compared with MEK; however, these MEK responsive cells had
less ERK activity when compared with the other models. Fur-
ther, both PN lines, which are less aggressive and have
increased SRC when compared with mesenchymal lines, dem-
onstrated relatively high levels of both Akt and MEK activation.
Collectively, these findings suggest that the downstream
Fig. 2. Glioblastoma cells demonstrate an attenuated spare respiratory capacity. (A, C and E) The respiratory phenotype was defined in the
described cell lines using established methods to study mitochondrial function that involved sequentially exposing cells to oligomycin (O),
carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone (FCCP) (F), and rotenone/antimycin (R/A) in real-time on the Seahorse platform. (B, D
and F) The relatively spare respiratory capacity (%) was calculated as (oxygen consumption rate [OCR] following FCCP – baseline OCR)/baseline
OCR. * P , .01.
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sequelae of pathway activation likely involves a complex signal-
ing network that eventually translates to their metabolic con-
sequences and reiterates the difficulty in identifying functional”
signaling pathways in a given tumor.
Ras-mediated Signaling Modulates Oxygen Consumption
Rate Through Inhibition of Pyruvate Dehydrogenase
Activity
Next, we investigated potential mechanistic underpinnings of
the observed Ras signaling-mediated regulation of OCR. Since
PDH represents a key gatekeeping enzyme that regulates
glycolytic flux into the mitochondria, we hypothesized that
oncogenic signaling associated with Ras pathway activation in-
hibited enzyme activity, thereby actively attenuating mitochon-
drial flux and maximal OCR. Although the role of PDH in
modulating glycolytic flux and baseline oxygen consumption
has been established, its capacity to regulate maximal OCR,
and thereby a cell’s mitochondrial SRC, has yet to be explored.
As an initial investigation to determine if changes in PDH activ-
ity could modulate SRC, we evaluated OCR in cells treated with
the metabolic modulator dichloroacetate (DCA). DCA has been
previously shown to inhibit PDH kinase (PDK), which is an
endogenous inhibitor of PDH. By inhibiting PDK, DCA in turn
activates PDH, allowing for increased glycolytic flux into the
Fig. 3. Ras-mediated signaling modulates oxygen consumption rate (OCR) and spare respiratory capacity through inhibition of pyruvate
dehydrogenase (PDH) activity. (A and B) The respiratory phenotype was defined in TR cells exposed to either vehicle control or the described
agents 24 hours prior to analysis. To study mitochondrial function, cells were sequentially exposed to oligomycin (O), carbonyl cyanide-4-
(trifluoromethoxy)phenylhydrazone (FCCP) (F), and rotenone/antimycin (R/A) in real time. The relative spare respiratory capacity (%) was
calculated as (OCR following FCCP – baseline OCR)/baseline OCR. (C) PDH enzyme activity in the described cell lines and treatment conditions
using a microplate assay kit. (D) Western blot was performed to determine levels of phosphorylated PDH (pPDH) in the described cell lines.
Levels were quantified by determining the pPDH/PDH ratio for each line and then normalized to the ratio of T cells. (E) Western blot was
performed to determine levels of pPDH in TR cells exposed to vehicle control or the stated agents. Levels were quantified by determining the
pPDH/PDH ratio for each treatment condition and then normalizing to the ratio of vehicle control cells. *P , .05.
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mitochondria and oxidative phosphorylation.25 TR cells ex-
posed to DCA (1mM) demonstrated an expected increase in
baseline OCR. In addition to baseline increases in OCR, DCA
was also shown to increase SRC at levels consistent with MEK
and/or Akt inhibition (Supplementary material, Fig. S4E and F).
We next evaluated the potential of these signaling pathways to
modulate PDH activity. As demonstrated in Fig. 3C, the addition
of DCA to U251 cells led to an expected increase in PDH activity,
increasing activity 2.6-fold. Interestingly, baseline PDH activity
of both T and TP lines was 2-fold higher than U251 cells, and
the addition of DCA only led to modest increases in enzyme ac-
tivity in these less aggressive lines. Conversely, the aggressive
TR lines demonstrated a similar level of baseline PDH activity
as U251 cells. Twenty-four hour exposure of TR lines to
MK2206 and AZD6244 led to increases in PDH activity (2.0
and 1.4-fold, respectively), which was consistent with their dif-
ferential capacity for modulating mitochondrial reserve capac-
ity (Fig. 3B). Interestingly, the levels of PDH activation following
Akt inhibition in the TR line were equivalent to DCA. Similar find-
ings were observed in U251 cells (Supplementary material,
Fig. S4G); although consistent with the above data (Supplemen-
tary material, Fig. S4A and B), this line was more responsive to
MEK inhibition. PDH activity is regulated by reversible phosphor-
ylation. Phosphorylation of PDH by PDH kinases (PDK1-4) inhib-
its its action and attenuates pyruvate use in the mitochondria
for oxidative phosphorylation, whereas dephosphorylation by
PDH phosphatases (PDP1-2) stimulates enzyme activity. We
evaluated the phosphorylation state of PDH in the T/R/P lines.
Consistent with enzyme activity studies, the TR line demon-
strated a high baseline level of PDH phosphorylation, which
was increased 3.7-fold when compared with both T and TP
lines (Fig. 3D). Further, these levels were decreased by 50%
following both MEK and Akt inhibition (Fig. 3E). Similar findings
of increased SRC and decreased PDH phosphorylation were ob-
served in TR cells following inhibition of AKT expression (Supple-
mentary material, Fig. S4H). Collectively, these findings further
support the role PDH activity plays in regulating maximal OCR
and SRC and how aberrant signaling pathways typical to GBM
modulate this phenotype.
Attenuated Pyruvate Dehydrogenase Activity and Spare
Respiratory Capacity Are Mediated Through Pyruvate
Dehydrogenase Phosphatase Downregulation
Since we had established that Ras-mediated signaling resulted
in deceased PDH activity, we next sought to determine its
mechanistic underpinnings. Since PDKs and PDPs represent
proteins regulating PDH activity, we determined if these en-
zymes were aberrantly expressed in our model. We identified
PDP1(and PDP2 to a lesser extent) to be downregulated in the
TR line, with an 80% and 60% decrease in messenger RNA lev-
els, respectively (Fig. 4A). Interestingly, their levels were re-
stored back to the levels in both T and TP following Akt and
MEK inhibition. Similar findings were observed when we evalu-
ated the protein expression of PDP1, with an approximately
2-fold increase in expression in TR following MEK and/or Akt in-
hibition (Fig. 4B). We next sought to demonstrate a causal link
between PDP1 expression and OCR/SRC since we had already
established that Ras-mediated signaling attenuates maximal
OCR and SRC and had demonstrated its potential to inhibit
PDH activity through downregulation of PDP1. We transiently
Fig. 4. Attenuated pyruvate dehydrogenase (PDH) activity and mitochondrial reserve capacity in glioblastoma are mediated through
downregulation of pyruvate dehydrogenase phosphatase (PDP) expression. (A) The PDH regulatory proteins PDP1-2 and PDK1-4 were evaluated
by reverse transcriptase PCR in the described cell lines and treatment conditions. Levels were quantified relative to actin and then normalized to the
T cell line. (B) Western blot was performed to determine levels of PDP1 expression in TR cells treated in the described conditions. (C) Western blot
was performed to determine levels of the stated proteins in T, TR, and the TR line overexpressing PDP1 (TR + PDP1). (D) The respiratory phenotype of
the described cell lines was determined using the Seahorse platform. (E) PDP1 expression in normal brain and GBM was evaluated on the The
Cancer Genome Atlas platform. *P , .01.
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overexpressed PDP1 in TR, resulting in an expected decrease in
PDH phosphorylation (Fig. 4C). Next, we directly evaluated the
role of PDP1 expression on the cells’ mitochondrial phenotype.
Similar to studies in TR cells following MEK and Akt inhibition,
transient overexpression of PDP1 did not influence baseline
levels of OCR; it did, however, result in restoration of SRC by in-
creasing it 36%+0.6% (Fig. 4D). Since we had already estab-
lished the capacity of aberrant signaling pathways typical in
GBM to downregulate PDP1 expression, we went on to evaluate
for PDP1 expression in human samples using the TCGA data-
base,10 which demonstrated significantly decreased levels of
PDP1 in GBM when compared with normal brain (Fig. 4E) and
further supported the interplay between Ras-mediated onco-
genic signaling in GBM and PDH regulation.
PDP1-mediated Regulation of Pyruvate
Dehydrogenase Activity Contributes To
Glioblastoma Tumorigenesis
To determine if observed changes in PDH activity and SRC in-
fluenced tumorigenesis, we generated stable TR lines that over-
expressed PDP1. We confirmed PDP1 overexpression in these
lines, along with their expected decrease in PDH phosphoryla-
tion and increase in SRC (Supplementary material, Fig. S6A–C).
We then evaluated the growth kinetics of these lines in vitro. Al-
though PDP1-overexpressing clones maintained viability, they
grew at a decreased rate when compared with vector controls
(Fig. 5A). Next, we evaluated in vivo growth rate using an s.c.
mouse xenograft model. Although a tumor was palpable in TR
clones overexpressing PDP1, they failed to grow larger than
30 mm3 when compared with vector controls (Fig. 5B and C).
Discussion
In this report, we have presented several novel findings that in-
volve unique metabolic states associated with gliomagenesis
and how these processes are modulated through oncogenic
signaling pathways. Initial studies focused on cellular metabo-
lism at baseline to define relative metabolism through oxidative
phosphorylation and aerobic glycolysis, which collectively sug-
gested that baseline metabolism has a limited capacity to
determine the tumorigenicity and/or aggressiveness of a
given cell line when grown in vitro. These results are not
completely unexpected because the metabolic programs
evolved during gliomagenesis are likely a direct consequence
of their need to adapt to the tumor microenvironment, which
is likely not recapitulated in in-vitro conditions devoid of oxygen
and nutrient restrictions. Furthermore, it is likely that several
factors play a role in maintaining an individual cell’s baseline
oxidative phosphorylation state including reliance on glycolysis
or alternate forms of energy metabolism (eg, glutamine me-
tabolism and/or fatty acid oxidation, and baseline levels of ox-
idative stress). These factors likely play a role in the observed
metabolic heterogeneity in these lines.
Based on these potential limitations associated with study-
ing the metabolic state of cell lines in baseline conditions, we
extended our investigations to determine if differential re-
sponse to bioenergetic stress were associated with and/or con-
tributed towards gliomagenesis. We uncovered an actively
regulated oxidative state involving attenuated mitochondrial
SRC associated with gliomagenesis. Our understanding about
the potential relevance of SRC, which is defined as the differ-
ence between the maximal unregulated respiration and the ini-
tial basal respiration of an individual cell line15 in both normal
Fig. 5. Modulation of pyruvate dehydrogenase (PDH) activity through PDP1 expression influences glioblastoma growth. (A) TR vector control cells
(TR_VC) and clones overexpressing PDP1 (TR_PDP1_c1/2) were evaluated growth kinetics were evaluated in vitro. (B) Tumor growth curves were
obtained in the described cell lines at stated times in an s.c. mouse xenograft model (n¼ 10/cell line) using perpendicular diameter measurements
of each tumor with digital calipers; volumes were calculated using the formula (LxWxW)/2. (C) A representative image of described cell lines grown
in an s.c. mouse xenograft model. *P , .01.
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and cancer cells, is continuing to evolve. It has been suggested
that reserve capacity is utilized to provide for increased energy
demands during stressed conditions. This was demonstrated to
be particularly relevant in cardiac tissue, which is rich in mito-
chondria and capable of dynamically responding to increased
bioenergetic demands during stressed conditions.23 In our
studies, this metabolic adaptation appeared to be maintained
in the nontumorigenic normal lines tested but was consistently
lost in GBM lines. Interestingly, recent studies support this as an
emerging tumor-specific metabolic phenotype. Sandulache
et al identified that loss of mitochondrial reserve capacity
was attributed to p53 mutation in squamous cell carcinoma,
conferring therapeutic resistance.26 Anso et al identified a
loss of SRC following myc-induced malignant transformation
of osteocytes to osteogenic sarcoma.27 Collectively, these find-
ings, coupled with our results performed on a diverse panel of
GBM lines, suggest that an attenuated SRC represents a meta-
bolic shift associated with tumorigenesis. However, the specific
biological advantage(s) offered to tumor cells by this metabolic
shift remain unclear. Again, our current understanding of the
SRC is that it allows normal cells to adapt to increased bioener-
getic demands during periods of short-term stress. However,
the GBM microenvironment poses a constant array of stresses
to an individual cell. Although vascularized tumors, newly
formed vessels in GBM are tortuous with compromised vascular
integrity. This limits tissue perfusion, resulting in a microenvi-
ronment with variable levels of hypoxia and nutrient depriva-
tion.28,29 Our findings, which demonstrate the capacity of
signaling pathways to attenuate maximal OCR and SRC, may
be particularly relevant in the context of intermittent hypoxia,30
as we hypothesize that it may be disadvantageous for cancer
cells to rely on compensatory increases in OCR long-term; this
could potentially lead to increased generation of reactive oxy-
gen species and cellular damage associated with increased ox-
idative phosphorylation.31,32
Next, we demonstrated that the observed changes in SRC
were a direct consequence of PDH activity. Although the central
regulatory role PDH plays in baseline oxidative phosphorylation
through modulation of glycolytic flux into the mitochondria is
well established, the secondary role of this gatekeeping en-
zyme has yet to be described. Further, its tight regulation by on-
cogenic signaling reinforces its potential implications in
tumorigenesis, contributing to tumorigenesis. We proceeded
to mechanistically link changes in PDH activity and SRC with
Ras pathway activation and demonstrated the ability to restore
SRC through targeted inhibition of its downstream effectors.
These findings add to the growing body of data demonstrating
the capacity of Ras signaling for modulating metabolic pro-
grams at multiple levels in cancer. Chiaradonna et al demon-
strated the role of oncogenic Ras in enhancing utilization of
the glycolytic pathway,33 and Ying et al identified the potential
of Ras to control glycolysis at several rate-limiting steps, which
led to shunting of glucose metabolism towards anabolic me-
tabolism.8 Our data provide further insight into the dynamic
role this oncogene plays in tumor metabolism. Interestingly,
we demonstrated that multiple signaling pathways have the
capacity to modulate PDP1 expression. Redundant signaling
pathways are commonly observed in cancer and allow cells
to maintain activity of key downstream circuits in the presence
of altered upstream ligand-dependent signaling and/or to
dynamically acquire resistance to targeted inhibition of a single
pathway. Further, the redundancy of AKT and MEK/ERK path-
ways has been described previously.34,35 Therefore, the ob-
served redundancy of these pathways further underscores
the potential biological importance of PDH regulation in con-
tributing to the aggressive phenotype of GBM and the potential
therapeutic limitations of targeting these upstream pathways
individually.
Lastly, we demonstrated that Ras-mediated regulation of
PDH activity and mitochondrial function was mediated through
the capacity of this pathway to attenuate expression of PDH
regulatory proteins PDPs. The potential for oncogenic signaling
typical of GBM to downmodulate expression of PDPs was vali-
dated in patient samples, with PDP1 expression being signifi-
cantly repressed in GBM compared with normal brain tissue
when evaluated from the TCGA dataset. More importantly, re-
storing expression of PDP1 in our model diminished tumorige-
nicity. Targeting the PDH/PDP1 axis may also have application in
GSCs, which studies have shown to have a unique metabolic
state when compared with differentiated cells.16 Although
the multiple roles Ras signaling plays in tumorigenesis are
well established, our findings demonstrated that targeting
this single downstream consequence of pathway activation
can completely revert tumorigenic potential of this oncopro-
tein. These findings are consistent with emerging data reinforc-
ing the central role played by alterations of PDH activity in the
oncogenic transformation following genetic mutation. Recent
discoveries involving the mechanistic underpinnings of
oncogene-induced senescence represent one of the most nota-
ble examples describing this important interplay between a
driver mutation and its functional, metabolic consequence.36
In these studies, it was shown that PDH was a crucial mediator
of senescence induced by BRAFV600E in normal melanocytes,
leading to activation of PDH through suppression of PDK1 and
induction of PDP2. This resulted in increased cellular respiration
and subsequent senescence secondary to redox stress. Abro-
gating this mutation-induced metabolic program led to onco-
genic transformation and, similar to our findings, restoring
PDH activity diminished tumorigenic potential. Our model dem-
onstrated that Ras signaling can modulate PDH activity solely
through regulation of PDPs without requiring alterations in
PDK1. These finding are consistent with TCGA data, which dem-
onstrated only aberrant expression of PDP1 in clinical samples.
This suggests a complex interplay between a specific mutation
and an individual cell’s capacity to regulate PDH activity
through a balance between PDH activators and inhibitors that
require further investigation. In addition, further work is still re-
quired to better understand the mechanisms contributing to
the differential metabolic response of normal cells and prema-
lignant and/or tumor cells to a specific genetic mutation. These
studies support the functional consequence of alterations in
PDH activity playing a central event driving tumorigenesis.
The therapeutic potential of these findings shows strong prom-
ise and is being actively investigated, including recent work
demonstrating antitumor activity of the PDH activator DCA in
GBM.25
In summary, using a diverse panel of GBM and normal lines,
we demonstrated that an attenuated SRC was a common met-
abolic phenotype of GBM. We established that this phenotype
was driven by signaling pathways typical to GBM and was a
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consequence of their capacity to inhibit PDH activity by attenu-
ating expression PDP1 and normalizing this metabolic pro-
gram’s diminished tumorigenic potential. These findings
provide further support for the central role that PDH regulation
plays in tumorigenesis and the scientific rationale to continue
to develop and test clinical strategies designed to activate
PDH as a form of anticancer therapy in GBM.
Supplementary Material
Supplementary material is available online at Neuro-Oncology
(http://neuro-oncology.oxfordjournals.org/).
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